跳轉至內容
Merck
全部照片(1)

文件

Y0000739

紫杉醇

European Pharmacopoeia (EP) Reference Standard

同義詞:

Paclitaxel

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C47H51NO14
CAS號碼:
分子量::
853.91
Beilstein:
1420457
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

paclitaxel

製造商/商標名

EDQM

mp

213 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

[H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7

InChI

1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

InChI 密鑰

RCINICONZNJXQF-MZXODVADSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Paclitaxel semi-synthetic for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

紫杉醇是一种有效的抗肿瘤和抗有丝分裂的紫杉烷类药物,可与 β-微管蛋白的N端结合,并使微管稳定,使细胞周期停滞在G2/M期。微管损伤通过依赖 JNK 的途径诱导细胞凋亡,随后通过不依赖 JNK 的途径诱导细胞凋亡,这可能与蛋白激酶 A(PKA)或 Raf-1 激酶的激活,进而导致 Bcl-2 磷酸化有关。通过 CYP2CB 的主要代谢物是 6α-羟基紫杉醇(6α-OHP)。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

注意

紫杉醇可在甲醇中进行酯交换反应,并在水溶液中发生水解。

其他說明

Sales restrictions may apply.

相關產品

產品號碼
描述
訂價

象形圖

Health hazard

訊號詞

Danger

危險聲明

危險分類

Muta. 2 - Repr. 1B - STOT RE 1

標靶器官

Central nervous system,Bone marrow,Cardio-vascular system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Miguel A Ojeda-Lopez et al.
Nature materials, 13(2), 195-203 (2014-01-21)
Bundles of taxol-stabilized microtubules (MTs)--hollow tubules comprised of assembled αβ-tubulin heterodimers--spontaneously assemble above a critical concentration of tetravalent spermine and are stable over long times at room temperature. Here we report that at concentrations of spermine several-fold higher the MT
Taroh Satoh et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(19), 2039-2049 (2014-05-29)
In Asian countries, paclitaxel once per week is used as second-line treatment in advanced gastric cancer, including human epidermal growth factor receptor 2 (HER2) -positive tumors. The role of anti-HER2 agents, including lapatinib, in this setting and population is unclear.
Eric Pujade-Lauraine et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32(13), 1302-1308 (2014-03-19)
In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC. Eligible patients had measurable/assessable OC that
George Au-Yeung et al.
Gynecologic oncology, 133(1), 16-22 (2014-04-01)
Obesity is an increasing health problem that is reported to influence chemotherapy dosing. The extent to which this occurs and whether this affects outcomes in ovarian cancer was unclear. To describe chemotherapy dosing practices in normal, overweight and obese patients
Markus Bender et al.
Blood, 125(5), 860-868 (2014-11-21)
Bone marrow megakaryocytes produce platelets by extending long cytoplasmic protrusions, designated proplatelets, into sinusoidal blood vessels. Although microtubules are known to regulate platelet production, the underlying mechanism of proplatelet elongation has yet to be resolved. Here we report that proplatelet

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務